Sotera Health Co SHC
We are a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. We are driven by our mission: Safeguarding Global Health®. We provide end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers in the United States and around the world. In 2025, our customers included over 40 of the top 50 medical device companies and nine of the top ten global pharmaceutical companies (based on revenue). Our services are an essential aspect of our customers' manufacturing processes and supply chains, helping to ensure sterilized medical products reach healthcare practitioners and patients. Most of our services are necessary for our customers to satisfy applicable government requirements.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.16B | $1.10B | $1.05B | $1.00B | $931.5M | $818.2M | $778.3M | — |
| Cost of revenue | $518.1M | $498.1M | $472.1M | $446.7M | $412.8M | $374.6M | $382.9M | — |
| Gross profit | $645.5M | $602.3M | $577.2M | $557.0M | $518.7M | $443.6M | $395.4M | — |
| SG&A | $252.8M | $242.6M | $236.7M | $245.7M | $198.2M | $178.5M | $147.5M | — |
| Total operating expenses | — | $304.7M | $300.5M | $308.7M | $261.9M | $237.6M | $211.8M | — |
| Operating income | — | $297.6M | $276.7M | $248.3M | $256.7M | $206.0M | $183.6M | — |
| Pre-tax income | $147.5M | $113.9M | $106.0M | -$243.1M | $175.7M | -$38.9M | -$916.0K | — |
| Income tax | $69.6M | $69.5M | $54.7M | $9.5M | $58.6M | $1.4M | $19.5M | — |
| Net income | $77.9M | $44.4M | $51.4M | -$233.6M | $116.2M | -$38.6M | -$20.9M | — |
| EPS, basic | 0.27 | 0.16 | 0.18 | -0.83 | 0.41 | -0.16 | -0.09 | — |
| EPS, diluted | 0.27 | 0.16 | 0.18 | -0.83 | 0.41 | -0.16 | -0.09 | — |
| Shares, diluted (wtd. avg.) | $286.4M | $284.9M | $283.2M | $280.1M | $279.4M | $237.7M | $232.4M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $344.6M | $277.2M | $301.7M | $396.3M | $106.9M | $102.5M | $63.0M | $96.8M |
| Receivables | $139.3M | $140.3M | $147.7M | $118.5M | $108.2M | $91.7M | — | — |
| Inventory | $54.4M | $49.2M | $48.3M | $37.1M | $54.3M | $34.1M | — | — |
| Total current assets | $613.4M | $526.0M | $557.2M | $645.0M | $346.0M | $315.0M | — | — |
| Goodwill | $1.10B | $1.08B | $1.11B | $1.10B | $1.12B | $1.12B | $1.04B | — |
| Other intangibles | $288.2M | $317.7M | $416.3M | $491.3M | $598.8M | $643.4M | — | — |
| Total assets | $3.26B | $3.07B | $3.13B | $3.12B | $2.79B | $2.76B | — | — |
| Accounts payable | $78.0M | $55.1M | $71.0M | $74.1M | $72.9M | $52.4M | — | — |
| Short-term debt | $14.0M | $14.8M | $4.8M | $197.1M | $0 | $0 | — | — |
| Total current liabilities | $249.6M | $191.0M | $230.7M | $791.6M | $161.2M | $140.6M | — | — |
| Long-term debt | $2.13B | $2.21B | $2.22B | $1.75B | $1.74B | $1.82B | — | — |
| Total liabilities | $2.66B | $2.67B | $2.69B | $2.77B | $2.20B | $2.31B | — | — |
| Retained earnings | -$532.1M | -$610.0M | -$654.4M | -$705.8M | -$472.2M | -$589.1M | — | — |
| Total equity | $606.0M | $404.9M | $443.7M | $350.2M | $586.1M | $454.6M | -$641.1M | $45.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $287.2M | $224.2M | -$147.7M | $278.0M | $281.5M | $120.6M | $149.0M | — |
| Depreciation and amortisation | $94.9M | $84.3M | $76.6M | $64.3M | $64.2M | $63.3M | $66.7M | — |
| Stock-based compensation | $30.9M | $36.8M | $32.2M | $21.2M | $13.9M | $11.0M | $6.9M | — |
| Capital expenditure | $138.0M | $179.1M | $215.0M | $182.4M | $102.2M | $53.5M | $57.3M | — |
| Investing cash flow | -$135.1M | -$179.0M | -$214.9M | -$181.9M | -$159.8M | -$158.7M | -$57.3M | — |
| Financing cash flow | -$100.5M | -$50.6M | $266.0M | $197.8M | -$117.3M | $73.4M | -$126.0M | — |
| Dividends paid | — | — | — | — | $0 | $0 | $691.2M | — |
| Buybacks | — | — | — | $0 | $0 | $34.0M | $0 | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-040937.
Others in SIC 8090
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| DVA | DAVITA INC. | $11.74B | 18.7x | 6.5% |
| PGNY | Progyny, Inc. | $1.99B | 39.9x | 10.4% |
| AGL | agilon health, inc. | $1.49B | — | -2.1% |
| VMD | VIEMED HEALTHCARE, INC. | $345.8M | 24.5x | 20.5% |
| CCEL | CRYO CELL INTERNATIONAL INC | $34.5M | — | -1.3% |
| MGRX | MANGOCEUTICALS, INC. | $8.9M | — | -26.0% |
| BRTX | BioRestorative Therapies, Inc. | $3.8M | — | -10.3% |
| FMS | Fresenius Medical Care AG | — | — | — |